Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

CD34+ Numbers

Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation

Bone Marrow Transplantation volume 31, pages 967–972 (2003)Cite this article

Summary:

The impact of the CD34+ cell dose on chronic graft-versus-host disease (cGVHD) and the clinical outcome was analyzed in 41 consecutive adult patients submitted to allogeneic peripheral blood stem cell transplantation from HLA-identical siblings. The patients were classified into ‘low’ or ‘high’ CD34+ cell dose groups based on whether they received less or more than a median CD34+ cell dose of 10.5 × 106/kg, respectively. There was a significant difference in the incidence of extensive cGVHD (low vs high group, 25.0 vs 66.7%, P=0.021) and relapse (47.6 vs 20.0%, P=0.049) between the two groups. With a median follow-up of 335 days, the 3-year survival estimate for the whole population was 47.9%, while that for the low and high groups was 29.9 and 67.8%, respectively (P=0.0434). An inverse relation was noted between the relapse rate and the incidence of extensive cGVHD (P=0.043). It would appear reasonable that the optimal dose of CD34+ cells should be determined based on the disease status or aggressiveness of the malignant cells in each patient. Yet, in the case of patients with a high risk of relapse, transplantation with a CD34+ cell dose of >10.5 × 106/kg would seem to be acceptable to minimize the risk of relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Barrett J, Bahceci E, Childs R et al. High CD34+ cell dose lowers relapse risk in standard and high-risk recipients of allogeneic bone marrow or peripheral blood stem cell transplants (PBSCT). Blood 1998; 92: 139a [abstract].

    Google Scholar 

  2. Mavroudis D, Read E, Cottler-Fox M et al. CD34+ cell dose predicts survival, post transplant mobidity and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229.

    CAS  PubMed  Google Scholar 

  3. Singhal S, Powles R, Treleaven J et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489–496.

    Article  CAS  PubMed  Google Scholar 

  4. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.

    Article  CAS  PubMed  Google Scholar 

  5. Bittencourt H, Rocha V, Chevret S et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726–2733.

    Article  CAS  PubMed  Google Scholar 

  6. Nakamura R, Bahceci E, Read EJ et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 2001; 115: 95–104.

    Article  CAS  PubMed  Google Scholar 

  7. Urbano-Ispizua A, Carreras E, Marin P et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells. Blood 2001; 98: 2352–2357.

    Article  CAS  PubMed  Google Scholar 

  8. Sohn SK, Kim JG, Seo KW et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81–86.

    Article  CAS  PubMed  Google Scholar 

  9. Thomas E, Storb R, Clift RA et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843.

    Article  CAS  PubMed  Google Scholar 

  10. Brunet S, Urbano-Ispizua A, Ojeda E et al. Spanish Group of Allogeneic-PBT. Spain. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114: 544–550.

    Article  CAS  PubMed  Google Scholar 

  11. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  PubMed  Google Scholar 

  12. Bahceci E, Read EJ, Leitman S et al. CD34+ cell dose predicts relapse and survival after T-cell depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 2000; 108: 408–414.

    Article  CAS  PubMed  Google Scholar 

  13. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221–3227.

    Article  CAS  PubMed  Google Scholar 

  14. Przepiorka D, Smith TL, Folloder J et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465–1470.

    CAS  PubMed  Google Scholar 

  15. Hagglund H, Bostrom L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747–753.

    CAS  PubMed  Google Scholar 

  16. Morariu-Zamfir R, Rocha V, Devergie A et al. Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 2001; 27: 575–580.

    Article  CAS  PubMed  Google Scholar 

  17. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666–1672.

    CAS  PubMed  Google Scholar 

  18. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655–1658.

    CAS  PubMed  Google Scholar 

  19. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659–1965.

    CAS  PubMed  Google Scholar 

  20. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  21. Lee SJ, Klein JP, Barrett AJ et al. Chronic graft-vs-host disease (cGVHD) severity score: effects on leukemia-free survival. Blood 2000; 96: 556a [abstract].

    Google Scholar 

  22. Ringden O, Barrett AJ, Zhang M et al. A high CD34+ cell dose is associated with improved leukemia-free survival in recipients of HLA-identical bone marrow or peripheral blood stem cells [abstract]. Blood 2001; 98: 413a.

    Google Scholar 

  23. Sohn SK, Jung JT, Kim DH et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002; 94: 18–24.

    Article  CAS  PubMed  Google Scholar 

  24. Remberger M, Ringden O, Blau IW et al. No difference in graft-versus-host disease relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739–1745.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Lorne Hwang for the careful review of our manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Kyungpook National University Hospital, Taegu, South Korea

    S K Sohn, J G Kim, D H Kim & K B Lee

  2. Department of Clinical Pathology, Kyungpook National University Hospital, Taegu, South Korea

    N Y Lee & J S Suh

Authors
  1. S K Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J G Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Y Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J S Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K B Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sohn, S., Kim, J., Kim, D. et al. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 31, 967–972 (2003). https://doi.org/10.1038/sj.bmt.1704042

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704042

Keywords

This article is cited by

Search

Advanced search

Quick links